
UK medical charity sells part of interest in MSD’s Keytruda for $150 million
pharmafile | July 15, 2016 | News story | Research and Development, Sales and Marketing | MSD, Merck, keytruda
UK medical research charity MRC Technology sold part of its royalty interest in US pharma major MSD’s (NYSE: MRK) immunotherapy Keytruda (pembrolizumab) for $150 million to raise funds for new research.
The charity sold part of the interest in a leading cancer drug to private equity fund managed by DRI Capital.
Keytruda is a new generation treatment which stimulates the body’s immune system to fight cancer. MRC Technology humanised the antibody-based treatment, which has been approved in the US to treat advanced melanoma and non-small cell lung cancer, with breakthrough designations under US Food and Drug Administration’s accelerated approval pathway awarded for colorectal cancer and classical Hodgkin Lymphoma.
A number of trials in other cancers are showing promising results.
Anjali Shukla
Related Content

Merck to acquire Curon Biopharmaceutical’s B-Cell Depletion Therapy
Merck have announced that they have entered into an agreement with private biotechnology company Curon …

Merck and Daiichi Sankyo expand development and commericalisation agreement to include MK-6070
Daiichi Sankyo and Merck (known as MSD outside of the US and Canada) have announced …

CHMP gives positive opinion for Merck’s KEYTRUDA for unresectable or metastatic urothelial carcinoma
Merck (known as MSD outside of the US and Canada) has announced that its anti-PD-1 …






